

EAPM DRAFT AGENDA



European Alliance for
Personalised Medicine

EAPM Conference at ESMO

***“The need for change – and how to make it happen
: Defining the healthcare ecosystem to determine value”.***

***Friday, September 17th, 2021
08.30 – 16.00 CET***

Overview

The theme of EAPM's ninth annual event during the ESMO Congress will be “*The Need for Change: Defining the healthcare ecosystem to determine value.*” High-level speakers and attendees will come from a wide range of stakeholder groups including patients, healthcare professionals, academics, industry representatives, politicians and legislators, the media and more.

Issues Discussed:

Since the opportunity clearly exists for input into EU thinking, what input should be made in the field of cancer? The most obvious need, given the current level of fragmentation of policy and practice, is for a new degree of coherence...

But coherence is not enough. A top-down imposition of new rules cannot be the answer if the essence of the EU's concern – the welfare of its citizens – is to have priority. The oft-cited mantra of patient-centred healthcare must also be given real meaning, and that implies a careful and thoughtful complement of bottom-up thinking too...

For both top-down and bottom-up strands to be brought successfully together, there must be a new degree of trust, too. The imposition of regulation and legislation cannot be the complete answer. It can create a more appropriate framework, but within that the promotion of innovation and of integration will always depend ultimately on voluntary cooperation.

All stakeholders will have to play their part in discussions and policy formation. And they will all have to accept that the ultimate objective is better health for patients. Their own interest and priorities must adapt to that priority.

For industry that could mean taking advantage of greater synergies in new models of clinical trials and drug development, making use of more sensitive and comprehensive data on delivery of therapeutic advantage - and with a more sophisticated relation between prices and demonstrated performance...

For health services it could mean more effective screening programmes ... using higher tech...low-dose radiation...

For institutions and member states it could mean more purposeful discussion – taking more account of input from stakeholders, avoiding repetition, and translating decisions into action...

In the Commission, the Council and the Parliament, it could mean closer links between their own internal departments and committees dealing with health, and closer links between all three of them in decision making.

For healthcare professionals it could mean openness to new ways of working, new techniques and technologies in screening, diagnosis and treatment, and a new focus on prevention – and

EAPM DRAFT AGENDA

readiness to undergo new training. For individual patients, this could mean new options for healthcare access – and new responsibilities for developing health literacy, so they too can play a bigger role in their own health and their treatment.

For Europe, beset by popular scepticism about politics, politicians and political systems, it could offer a powerful antidote to public hostility and populist disenchantment with technology and globalisation. At the level that matters most to everyone, their own personal interest, a recalibration of policy towards the patient could not only improve health, but restore faith in Europe itself.

This dynamics series of roundtable will look at different elements of this through the following sessions:

- Session I: Winning Stakeholders' Trust In Genomic Data Sharing and the use of Real World Evidence/Data
- Session II: Bringing Molecular Diagnostics into healthcare Systems
- Session III Regulating the future - Balance of patient safety and facilitating innovation – IVDR
- Session IV: 'Saving lives through Health Data collection and usage

08.30 – 10.45 Session I: Winning Stakeholders' Trust in Genomic Data Sharing and the use of Real-World Data/Evidence

This session will look at different aspects of the issue around the use of data in terms of Real World Evidence/Data

Welcome: **D. Horgan**, *Executive Director, European Alliance for Personalised Medicine*

Chair: **Antoni Monserrat**, *Former Senior Expert on Cancer and rare Disease, DG SANTE*
(Confirmed)

08.30 – 09.10 Setting the Scene: Citizen's Trust, Public Trust and Healthcare

- **Cristian Busoi MEP**, *ENVI Committee, European Parliament (10 minutes)*
- **Christine Chomienne**, *Vice President, Cancer Mission Boards (10 Minutes) (Confirmed)*
- **Dipak Kalra**, *President, The European Institute for Innovation through Health Data (i~HD) (Confirmed)*
- **Niko Andre**, *interim Vice-President, Head of Oncology Europe and Canada, and Global Franchise Head Hematology - Oncology Business Unit, AstraZeneca (confirmed)*
- **Professor Sir Mark Caulfield**, *Former Chief Scientist, Genomics England(10 Minutes) (Confirmed)*

Q&A

09.10– 10.20 Stakeholder Perspective

European Commission

- **Szymon Bielecki**, *DG CONNECT, European Commission (Confirmed)*

EUnetHTA

- **Niklas Hedberg**, *Chief Pharmacist at the governmental authority, the Dental and Pharmaceuticals Benefits Agency (TLV), in Sweden. (10 Minutes) (Confirmed)*
-

Patient Expert Perspective

- **Bettina Ryll**, *Melanoma Patient Network Europe, Sweden. (Confirmed)*

EAPM DRAFT AGENDA

Central Easter Europe:

- **Jasmina Koeva**, Country Representative, 1 +MG ([Confirmed](#))

European Reference Networks:

- **Birutė Tumiene**, Vilnius University Hospital ([Confirmed](#))

Italy

- **Arturo Chiti**, Humanitas University, Milan, Italy ([Confirmed](#))

Discussion

Q&A

10.20 – 10.30 **Conclusion**

BREAK

10.45– 12.30 Session II: Bringing Molecular Diagnostics into healthcare Systems

Chair: D. Horgan, Executive Director, European Alliance for Personalised Medicine

10.45– 11.00 **Setting the Scene**

- **Benedikt Westphalen**, Koordinator Molekulare Onkologie, Comprehensive Cancer Centre, University of Munich ([Confirmed](#))
- **Peter Liese**, European People's Party, ENVI Committee, European Parliament

11.00 – 12.15 **Country Perspective & European Union & Stakeholders**

European Commission

Stefan Schreck, Adviser for Stakeholders relations, DG SANTE, European Commission ([Confirmed](#))

Lung cancer: disparities in access to diagnosis and treatment and the activation of EPROPA program in Romania

- **Stefania Vallone**, WALCE Italy & **Prof. Laura Mazilu** (Romania) ([Confirmed](#))

Slovenia

- **Tanja Cufer**, Professor of Oncology, Medical Faculty, University of Ljubljana (10 Minutes) ([Confirmed](#))

Germany

- **Olaf Rieß**, University of Tübingen, Tübingen, Germany (10 Minutes) ([Confirmed](#))

Public Private Cooperation

- **Gilles Erb, PhD**, Senior Global Medical Science Director, F. Hoffmann-La Roche ([Confirmed](#))

Ireland

- **William Gallagher**, University College Dublin, Dublin, Ireland ([Confirmed](#))

12.15 – 12.30 **Conclusion**

12.30– 13.30. Lunch

13.30– 14.30 Session III: Regulating the future - Balance of patient safety and facilitating innovation - IVDR

Chair: **Denis Horgan, Executive Director, European Alliance for Personalised Medicine**

This session will focus on the issues relating to the transposition of the IVDR and the impact on cancer diagnostics

Member States

Ortwin Schulte, *Health Attaché, Permanent Representation of Germany to the EU*

Germany

- **Monika Brüggemann**, *Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.* ([Confirmed](#))

France

- **Paul Hofman**, *Head of the Laboratory of Clinical and Experimental Pathology at the University Hospital Nice, France* ([Confirmed](#))

Access

- **Mélanie Yammine**, *Director EU Government Affairs, Astellas Pharma Europe Ltd.* ([Confirmed](#))

Italy

Ettore Capoluongo, *University of Naples Federico II, Naples, Italy* ([Confirmed](#))

Q&A

Discussion

14.30 – 14.45 Conclusion

14.45– 15.45 Session IV: 'Saving lives through Health Data collection and usage

Chair: **D. Horgan**, *Executive Director, European Alliance for Personalised Medicine*

This session will focus on the issues relating to a call to Action that Data Saves patients lives.

Speaker include:

- **Zorana Maravic**, *Acting CEO, Digestive Cancer Europe* ([Confirmed](#))
- **Kathi Apostolidis**, *Vice President, European Cancer Patient Coalition* ([Confirmed](#))
- **Susanne Baars**, *Sr. Global Thought Leadership Manager for expanding Precision Medicine, Siemens Healthineers* ([Confirmed](#))
- **Stanimir Hasardzhiev**, *Secretary General, Access Partnership* ([Confirmed](#))

15.45 – 16.00 Conclusion

End of Conference
